Stocks
Neuphoria Therapeutics Inc.NEUP
NASDAQHealthcareBiotechnology$3.48
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing therapies for neurological and psychiatric disorders, with a focus on treatments for major depressive disorder and other central nervous system conditions. Its lead programs target novel mechanisms, and investors track the stock for its pipeline milestones and potential regulatory catalysts.
52W Range: $3.19-$8.44
Congressional Interest in Neuphoria Therapeutics Inc. (NEUP)
No congressional trades have been disclosed for Neuphoria Therapeutics Inc. (NEUP) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading NEUP?
No congressional trades found for this stock.